search
close_mark

Strategic Regulatory Consulting for Ancillary Medicinal Substances and Clinical Evidence

Strategic Regulatory Consulting for Ancillary Medicinal Substances and Clinical Evidence

Project Summary

A medical device/combination product manufacturer partnered with Celegence for expert regulatory consulting to support EU MDR compliance. The engagement focused on a product incorporating an ancillary medicinal substance (PHMB coating), where regulatory and clinical evidence challenges created uncertainty about the product’s future under MDR.

Celegence provided regulatory GAP analysis and strategic recommendations, assessing the client’s product portfolio against EU MDR expectations and delivering actionable insights for decision-making.

Celegence Solution & Approach:

Celegence supported the client with:

Highlights:

check-marks

Conducting a regulatory GAP analysis for the medicinal substance component (PHMB coating)

check-marks

Reviewing baseline clinical documentation: Intended Purpose, SOTA, PSURs, and similarity justifications

check-marks

Assessing data against EU MDR and MDCG guidance to identify minimum data requirements and blockers

check-marks

Delivering a checklist and report analyzing open sections of 3.2.S/P, GMP considerations, and technical documentation readiness

check-marks

Developing a comprehensive strategy document, including conformity pathway recommendations (per MDCG-2023-7)

check-marks

Creating a roadmap for addressing gaps and strengthening regulatory compliance

Project Achievements

The client gained clarity on regulatory expectations and potential risks related to ancillary medicinal substances. Celegence’s expertise enabled the client to:

check-marks

Identify compliance gaps and data needs early

check-marks

Strategically plan the future of their product portfolio

check-marks

Make an informed, evidence-based decision on product continuation

check-marks

Align clinical evidence and documentation with MDR and MDCG guidance

Project Success

Close collaboration between Celegence experts and the client team ensured that tailored, strategic insights were delivered quickly and effectively. By combining regulatory know-how with structured analysis, the engagement provided the client with both immediate guidance and a long-term roadmap for MDR compliance..

Need EU MDR-Compliant Strategies for Combination Products?

Celegence delivers expert regulatory consulting, GAP analysis, and strategic recommendations for ancillary medicinal substances and clinical evidence - helping you plan with confidence.

Learn More

Other Related Articles

View All

Contact Us Today

From document publishing automation to eCTD submissions and beyond, Celegence is your trusted partner for regulatory affairs excellence. Contact us to learn how we can help you achieve your compliance goals efficiently and cost-effectively.

"*" indicates required fields